SLAMF7 and plasma cell myeloma: Taking these studies together, while the consequences of fratricide of both anti-SLAMF7 CAR T cells and other immune cells require further investigation, it appears that anti-SLAMF7 CAR T cells could be a promising therapeutic strategy for the treatment of myeloma.